Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy

Supportive Care in Cancer

Volumn 14, Issue 12, 2006, Pages 1184-1194

  Aapro, Matti S ^a   Dale, David C ^b   Blasi, Michael ^c   Sarokhan, Brenda ^c   Ahmed, Fawzia ^d   Woodman, Richard C ^c  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Ortho Biotech Products LP   (United States)

^d ANALYSIS GROUP   (United States)

Author keywords

Anemia; Cancer chemotherapy; Epoetin alfa; Geriatric; Hemoglobin

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY RELATED ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; DIGESTIVE SYSTEM CANCER; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; GERIATRIC PATIENT; GYNECOLOGIC CANCER; HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HODGKIN DISEASE; HUMAN; LINEAR ANALOG ASSESSMENT SCALE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES;

EID: 33751288868     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0076-z     Document Type: Article

References (30)

1. Aapro MS, Cella D, Zagari M (2002) Age, anemia, and fatigue. Semin Oncol 29(Suppl 8):55-59
2. Baraldi-Junkins CA, Beck AC, Rothstein G (2000) Hematopoeisis and cytokines: relevance to cancer and aging. Hematol Oncol Clin North Am 14:45-61
3. Begg CB, Carbone PP (1983) Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 52:1986-1992
4. Beguin Y (1998) Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 25(Suppl 7):27-34
5. Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G (1995) Recombinant human erythropoietin treatment in geriatric cancer patients with cisplatin-associated anemia. Oncology 52:422-426
6. Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(Suppl 2):13-19
7. Cella D (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25(Suppl 7):43-46
8. Christman K, Muss HB, Case LD, Stanley V (1992) Chemotherapy of metastatic breast cancer in the elderly: the Piedmont Oncology Association experience. JAMA 268:57-62
9. Curt GA, Breitbart W, Cella D et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5:353-360
10. Demetri GD, Kris M, Wade J, Degos L, Cella D, for the Procrit Study Group (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16:3412-3425
11. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882
12. Gelman RS, Taylor SG IV (1984) Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 2:1404-1413
13. Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB 3rd (1994) Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 12:2447-2452
14. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S, for the Procrit Study Group (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218-1234
15. Gough IR, Furnival CM, Schilder L, Grove W (1983) Assessment of the quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 19:1161-1165
16. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS (1999) Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341:2061-2067
17. Kennedy BJ (2000) Aging and cancer. Oncology 14:1731-1733
18. Lichtman SM, Skirvin JA (2000) Pharmacology of antineoplastic agents in older cancer patients. Oncology 14:1743-1755
19. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B, for the Epoetin Alfa Study Group (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874
20. McCormack HM, de L Horne DJ, Sheather S (1988) Clinical applications of visual analog scales: a critical review. Psychol Med 18:1007-1019
21. Naeim A, Reuben D (2001) Geriatric syndromes and assessment in older cancer patients. Oncology 15:1567-1580
22. National Comprehensive Cancer Network (2006) Cancer- and treatment-related anemia: clinical practice guidelines in oncology, Version 2.2006
23. Patrick DL, Gagnon DD, Zagari MJ, Mathijs R, Sweetenham J, for the Epoetin Alfa Study Group (2003) Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 39:335-345
24. PROCRIT (epoetin alfa) (prescribing information) (2005) Ortho Biotech Products, L.P., Raritan, New Jersey
25. Quirt I, Robeson C, Lau CY et al, and the Canadian Eprex Oncology Study Group (2001) Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19:4126-4134
26. Shasha D, George M (2002) Rapid hemoglobin response in anemic cancer patients undergoing chemotherapy or chemoradiation therapy receiving once-weekly epoetin alfa treatment (abstract). Blood 11(pt 2):17b
27. Shasha D, George MJ, Harrison LB (2003) Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy [abstract]. Cancer 98:1072-1079
28. Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 23:2606-2617
29. Wu AW, Revicki DA, Jacobson D, Malitz FE (1997) Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 6:481-493
30. Yancik R, Ganz PA, Varricchio CG, Conley B (2001) Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 19:1147-1151